SCHEMBL3963947

SCHEMBL3963947

O=c1[nH]c2ccccc2cc1-c1ccncc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 9/20 0.68
CDK5R1 Q15078 9/20 0.68
KDR P35968 3/20 0.60
CHEK1 O14757 1/20 0.60
PDGFRB P09619 1/20 0.56
FGFR1 P11362 1/20 0.56
HSD17B10 Q99714 3/20 0.53
KDM4E B2RXH2 2/20 0.53
HPGD P15428 1/20 0.53
BRD4 O60885 1/20 0.50
DAO P14920 1/20 0.50
DDO Q99489 1/20 0.50
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIN2B Q13224 1/20 0.48
GRIN2C Q14957 1/20 0.48
GRIN3A Q8TCU5 1/20 0.48
PDE3B Q13370 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29712353 0.86 KDR (0.68) CDK5CDK5R1KDRCHEK1PDGFRB
SCHEMBL2008746 0.86 KDR (0.68) CDK5CDK5R1KDRCHEK1PDGFRB
SCHEMBL5458364 0.83 CDK5 (0.83) CDK5CDK5R1KDM4E
SCHEMBL5464992 0.82 CDK5 (1.00) CDK5CDK5R1
SCHEMBL11034067 0.81 DAO (0.58) CDK5CDK5R1KDRCHEK1PDGFRB
SCHEMBL11178624 0.80 KDM4E (0.60) CDK5CDK5R1KDRCHEK1PDGFRB
SCHEMBL30740091 0.80 KDR (0.60) CDK5CDK5R1KDRCHEK1PDGFRB
SCHEMBL11347026 0.80 CDK5 (0.65) CDK5CDK5R1KDRCHEK1PDGFRB
SCHEMBL30740090 0.80 KDM4E (0.60) CDK5CDK5R1KDRCHEK1PDGFRB
SCHEMBL29206326 0.80 BRD4 (0.64) CDK5CDK5R1KDRCHEK1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180312496-A1 BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS ORION CORP (FI) 2018-11-01 US claimed
US-20180312496-A1 BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS ORION CORP (FI) 2018-11-01 US disclosed
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2009-06-25 US disclosed
US-7498325-B2 Modified amino acids, pharmaceuticals containing these compounds and method for their production KARL THOMAS GMBH (DE) 2009-03-03 US disclosed
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2004-10-28 US disclosed
CN-1129605-C Modified aminoacids, pharmaceuticals containing these compounds and method for their prodn. THOMAE GMBH DR K (DE) 2003-12-03 CN disclosed
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production RUDOLF KLAUS (DE) 2003-04-10 US disclosed
US-6344449-B1 HEADACHE AND MORPHINE DEPENDENCE DR. KARL THOMAE GMBH (DE) 2002-02-05 US disclosed
US-20010036946-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production RUDOLF KLAUS (DE) 2001-11-01 US disclosed
CN-1230196-A Modified aminoacids, pharmaceuticals containing these compounds and method for their prodn. THOMAE GMBH DR K (DE) 1999-09-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, CHRM1, SRMS CDK5 2149/4885CDK5R1 2190/4885KDR 2713/4885
US-20180312496-A1 BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD1, BRD4, BRD2 CDK5 104/4885CDK5R1 60/4885KDR 3537/4885
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, SRMS, OPRM1 CDK5 2538/4885CDK5R1 2842/4885KDR 3333/4885
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production SLC1A5, NEFM, SRMS CDK5 2521/4885CDK5R1 2817/4885KDR 3523/4885
US-20010036946-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, SRMS, OPRM1 CDK5 2538/4885CDK5R1 2842/4885KDR 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.